Breaking News Instant updates and real-time market news.

CLVS

Clovis

$35.77

-1.51 (-4.05%)

, AZN

AstraZeneca

$32.11

-0.15 (-0.46%)

10:16
10/07/16
10/07
10:16
10/07/16
10:16

Piper still sees Clovis' rucaparib getting broader indication than Lynparza

Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.

CLVS

Clovis

$35.77

-1.51 (-4.05%)

AZN

AstraZeneca

$32.11

-0.15 (-0.46%)

TSRO

Tesaro

$99.89

-2.45 (-2.39%)

  • 07

    Oct

  • 08

    Oct

  • 06

    Nov

  • 16

    Nov

  • 11

    Jan

  • 23

    Feb

CLVS Clovis
$35.77

-1.51 (-4.05%)

10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
09/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the risk in the shares is "less than what the market assumes." 2. Barclays (BCS) upgraded to Buy from Hold at HSBC citing the pending disposal of non-core businesses and resulting value creation. 3. Etsy (ETSY) upgraded to Buy from Neutral at Monness Crespi with the firm's analyst believing that Etsy shares can still move higher and sees a solid opportunity for upward revisions from improving conversion rates due to enhanced search and mobile functionality, expanding take rates, and advanced cross-boarder commerce capabilities with vendors. 4. Clovis (CLVS) upgraded to Outperform from Neutral at Credit Suisse with analyst Kennen MacKay saying the potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition." 5. Jabil Circuit (JBL) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying the company's cash flow is nearing an inflection amid an upturn in its Apple (AAPL) business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZN AstraZeneca
$32.11

-0.15 (-0.46%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/12/16
09/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Buy from Neutral at SunTrust with analyst Robert Peck saying he thinks that a new interactive offering by the company could raise its contribution profit by 4%-9% and that the Street's 2017 estimates for the company "seem conservative." The analyst added that he thinks it's "very possible" that Pandora will be acquired. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying the company's MYSTIC oncology study could drive 39% share upside if successful. 3. Apache (APA) and upgraded to Overweight from Neutral at Atlantic Equities and to Peer Perform from Underperform at Wolfe Research. 4. Philip Morris (PM) upgraded to Conviction Buy from Neutral at Goldman with analyst Judy Hong saying she is increasingly bullish on the prospects of Next Generation Products and expects them to contribute 5%-6% of earnings by 2020. 5. Wal-Mart (WMT) upgraded to Outperform from Market Perform at Cowen with analysts led by Oliver Chen saying price investments, integration of physical and digital, and the Jet acquisitions position the company to regain its dominance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TSRO Tesaro
$99.89

-2.45 (-2.39%)

09/26/16
BOFA
09/26/16
NO CHANGE
Target $109
BOFA
Buy
TESARO price target raised to $109 from $95 at BofA/Merrill
BofA/Merrill analyst Doug Leggate raised Teseor's price target to $109 from $95 following management meetings that suggest current EBITDA is about $800M, ahead of management targets. Shares are Buy rated.
09/21/16
RHCO
09/21/16
NO CHANGE
Target $38
RHCO
Buy
Clovis well positioned for upside amid M&A speculation, says SunTrust
SunTrust analyst Peter Lawson attributes yesterday's afternoon rally in shares of Clovis Oncology (CLVS) to speculation of unconfirmed takeover interest from Eli Lilly (LLY). Clovis is a "pure play in one of the hottest areas of oncology" and could take the lead in the treatment setting in ovarian cancer for PARP inhibitors, Lawson tells investors in a research note. He expects launch of Clovis PARP inhibitor rucaparib in early 2017. The company is well positioned for upside and as a potential takeover target, Lawson contends. He finds market commentary around the PARP inhibitor companies, such as Clovis and TESARO (TSRO), as not surprising. The analyst has a Buy rating on Clovis with a $38 price target. Credit Suisse this morning upgraded the shares to Outperform citing the potential for a buyout.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Outperform
PARP addition makes sense for Eli Lilly oncology, says Leerink
In the wake of recent speculation that Eli Lilly (LLY) has expressed interest in acquiring Clovis (CLVS), Leerink analyst Seamus Fernandez says the addition of a PARP inhibitor makes strategic sense, fitting in "extremely well" with the former's oncology portfolio. Further, the analyst believes that the "impressive" emerging data from the PARP inhibitor class is likely to place both TESARO (TSRO) and Clovis high on the list of potential M&A targets. Fernandez reiterates an Outperform rating on Eli Lilly's shares.

TODAY'S FREE FLY STORIES

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

, TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

20:04
04/25/17
04/25
20:04
04/25/17
20:04
Hot Stocks
FCC chairman vows review of media ownership rules »

In a speech to the…

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

CBS

CBS

$66.41

0.46 (0.70%)

NXST

Nexstar

$68.90

0.3 (0.44%)

CMCSA

Comcast

$38.49

0.48 (1.26%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 09

    May

  • 22

    May

  • 23

    May

  • 15

    Jun

FB

Facebook

$146.49

1.02 (0.70%)

19:57
04/25/17
04/25
19:57
04/25/17
19:57
Periodicals
Facebook tests news discovery methods, The Information says »

Facebook is testing new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AVGO

Broadcom

$223.20

1.96 (0.89%)

, BRCD

Brocade

$12.58

0.01 (0.08%)

19:54
04/25/17
04/25
19:54
04/25/17
19:54
Periodicals
Broadcom, Brocade offer behavioral remedies to EU regulators, CTFN says »

Broadcom (AVGO) has…

AVGO

Broadcom

$223.20

1.96 (0.89%)

BRCD

Brocade

$12.58

0.01 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$146.49

1.02 (0.70%)

19:52
04/25/17
04/25
19:52
04/25/17
19:52
Hot Stocks
Facebook tests expanded 'Related Articles' feature »

Facebook announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

19:47
04/25/17
04/25
19:47
04/25/17
19:47
Periodicals
Trump administration considers additional trade actions, WSJ says »

The Trump administration…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

, PEP

PepsiCo

$114.16

-0.16 (-0.14%)

19:25
04/25/17
04/25
19:25
04/25/17
19:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

PEP

PepsiCo

$114.16

-0.16 (-0.14%)

BA

Boeing

$183.51

1.45 (0.80%)

UTX

United Technologies

$116.87

0.55 (0.47%)

TMO

Thermo Fisher

$158.81

1.47 (0.93%)

GD

General Dynamics

$193.24

1.33 (0.69%)

ANTM

Anthem

$172.46

4.05 (2.40%)

NOC

Northrop Grumman

$248.13

-1.01 (-0.41%)

WM

Waste Management

$74.23

0.13 (0.18%)

IR

Ingersoll-Rand

$85.66

1.47 (1.75%)

DPS

Dr Pepper Snapple

$98.41

0.16 (0.16%)

HES

Hess Corp.

$48.64

0.98 (2.06%)

WYN

Wyndham

$92.22

0.43 (0.47%)

FLIR

FLIR Systems

$37.51

0.27 (0.73%)

NDAQ

Nasdaq

$70.53

0.08 (0.11%)

STT

State Street

$80.62

0.83 (1.04%)

APH

Amphenol

$72.18

0.25 (0.35%)

ROK

Rockwell Automation

$160.14

3.19 (2.03%)

BAX

Baxter

$53.21

-0.24 (-0.45%)

NSC

Norfolk Southern

$116.78

-0.27 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 06

    May

  • 11

    May

  • 17

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

  • 15

    Jun

VZ

Verizon

$46.70

-0.35 (-0.74%)

19:20
04/25/17
04/25
19:20
04/25/17
19:20
Hot Stocks
Verizon introduces unlimited prepaid plan »

Verizon announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

NTB

Butterfield

$32.19

0.07 (0.22%)

19:12
04/25/17
04/25
19:12
04/25/17
19:12
Earnings
Butterfield reports Q1 core EPS 70c, consensus 64c »

Reports Q1 revenue $107M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NBIX

Neurocrine

$53.62

1.84 (3.55%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
Neurocrine prices 30-count bottle of Ingrezza at $5,275 »

Neurocrine disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

MNOV

MediciNova

$5.57

0.14 (2.58%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
MediciNova: Survival rate from MN-166 open-label period 'significantly higher' »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FOX

21st Century Fox

$29.89

0.14 (0.47%)

, FOXA

21st Century Fox

$30.61

0.26 (0.86%)

18:50
04/25/17
04/25
18:50
04/25/17
18:50
Periodicals
8 more employees join Fox News lawsuit over race discrimination, FT says »

Eight current and former…

FOX

21st Century Fox

$29.89

0.14 (0.47%)

FOXA

21st Century Fox

$30.61

0.26 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

, CG

Carlyle Group

$16.70

0.05 (0.30%)

18:44
04/25/17
04/25
18:44
04/25/17
18:44
Periodicals
Albany Molecular receives interest from Pamplona, Carlyle, Bloomberg says »

Albany Molecular (AMRI)…

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

CG

Carlyle Group

$16.70

0.05 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 06

    Jun

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:11
04/25/17
04/25
18:11
04/25/17
18:11
Hot Stocks
Pain Therapeutics sees completing additional Remoxy studies by year end »

"As previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:10
04/25/17
04/25
18:10
04/25/17
18:10
Hot Stocks
Breaking Hot Stocks news story on Pain Therapeutics »

Pain Therapeutics backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:09
04/25/17
04/25
18:09
04/25/17
18:09
Earnings
Pain Therapeutics reports Q1 EPS (6c), one estimate (6c) »

Reports Q1 net cash usage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PHG

Philips

$34.69

0.14 (0.41%)

18:04
04/25/17
04/25
18:04
04/25/17
18:04
Hot Stocks
Philips Lighting repurchases 3.5M shares for roughly EUR101M »

Philips Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$22.56

0.26 (1.17%)

, WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

18:03
04/25/17
04/25
18:03
04/25/17
18:03
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

PBF

PBF Energy

$22.56

0.26 (1.17%)

WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

SWC

Stillwater Mining

$17.99

0.09 (0.50%)

SBGL

Sibanye Gold

$8.14

-0.28 (-3.33%)

ARI

Apollo Commercial

$18.93

0.05 (0.26%)

ZLTQ

ZELTIQ

$56.49

-0.005 (-0.01%)

AGN

Allergan

$238.22

1.24 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 31

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:02
04/25/17
04/25
18:02
04/25/17
18:02
Hot Stocks
Frontline says makes new offer to DHT Holdings »

Frontline (FRO) issued…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBI

First Midwest

$24.11

0.16 (0.67%)

18:01
04/25/17
04/25
18:01
04/25/17
18:01
Earnings
First Midwest reports Q1 adjusted EPS 34c, consensus 33c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 17

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:00
04/25/17
04/25
18:00
04/25/17
18:00
Hot Stocks
Breaking Hot Stocks news story on Frontline, DHT Holdings »

Frontline says makes new…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFLY

Shutterfly

$51.46

0.18 (0.35%)

17:58
04/25/17
04/25
17:58
04/25/17
17:58
Hot Stocks
Shutterfly to retire MyPublisher brand and cite in Q2 »

Comment from company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HBNC

Horizon Bancorp

$27.24

0.37 (1.38%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Horizon Bancorp reports Q1 adjusted EPS 34c, consensus 41c »

Reports Q1 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

KMT

Kennametal

$40.48

1.15 (2.92%)

17:56
04/25/17
04/25
17:56
04/25/17
17:56
Hot Stocks
Kennametal sees restructuring yielding annual pre-tax savings $165M-$180M »

"Restructuring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 30

    May

  • 31

    May

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:56
04/25/17
04/25
17:56
04/25/17
17:56
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.